IBC's 23rd Annual International Conference - Antibody Engineering
2nd December 2012 — 6th December 2012

Dedicated to Delivering Scientific Research & Clinical Results

The world's most respected protein engineering and science meeting just got even better! Now in its 23rd year, this true scientific program covers the full spectrum of challenges in this space from basic science through clinical development.

Leading Academic Research

• Massachusetts Institute of Technology improves the EGFR downregulation to control the growth of tumors
• University of California, San Francisco explores clinical results of B cell depleting antibodies with reductions in markers of CNS disease activity
• Cambridge University uses blocking antibodies to control the microenvironment that supports tumor growth and invasion
• The Scripps Research Institute demonstrates the most effective animal models in evaluating human antibodies against HIV

Innovative Emerging Science

• Chugai Pharmaceutical Co. uses recycling technology that binds a single antibody to an antigen multiple times for improved antigen targeting
• Cell Signaling Technology combines mass spectrometry and DNA sequencing to rapidly identify antigen-specific monoclonal antibody sequences directly from circulating polyclonal serum
• Zyngenia outlines PK and toxicity non-human primate studies of a bispecific therapeutic for inflammatory diseases that fuses an Ang-2 targeting peptide to the anti-TNF-α antibody adalimumab
• Los Alamos National Laboratory applies ion torrent sequencing to analyze large antibody libraries and outputs of selections

Proven Clinical Results

• Seattle Genetics evaluates combination therapies of anti-CD30 antibodies with chemotherapeutic agents for the treatment of lymphoma
• Pfizer outlines phase III results of an anti-CD22 antibody being developed as a monotherapy and in combination with immunotherapy and non-targeted cytotoxics
• Amgen presents clinical data and future prospects for a bispecific antibody construct with dual specificity for CD19 and CD3
• University of Texas Southwestern examines clinical studies of Bavituximab used to overcome immune suppression in tumors

Expected Number of Attendees

NA

View Conference Website: IBC's 23rd Annual International Conference - Antibody Engineering

Price of Attendance

n/a

Brochure

View Event Brochure

Location

Hilton San Diego Bayfront Hotel
San Diego
United States
CA